CAS NO: | 2381037-82-5 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | RBN-2397 is a potent, accross species and orally active NAD+competitive inhibitor ofPARP7(IC50<3 nm). rbn-2397 selectively binds toPARP7(Kd=0.001 μM) and restores IFN signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors[1][2]. | ||||||||||||||||
IC50& Target[2] |
| ||||||||||||||||
体外研究 (In Vitro) | RBN-2397 (0.0001-100 μM; 24 hours) inhibits cells proliferation with an IC50value of 20 nM in NCI-H1373 lung cancer cells[2].RBN-2397 (0.4 nM-1 μM; 24 hours) shows a restoration of type I IFN response by an increase in STAT1 phosphorylation as a dose-dependent manner in NCI-H1373 human lung cancer cells[2].RBN-2397 (0.0001-1 μM; 24 hours) inhibits cell MARylation in a cell biochemial assay with an EC50value of 1 nM[2]. Cell Proliferation Assay[2]
Western Blot Analysis[2]
| ||||||||||||||||
体内研究 (In Vivo) | RBN-2397 (oral administration; 3-100 mg/kg; once daily; 24-32 days) induces tumor-specific adaptive immune memory in CT26 syngeneic model with durable complete responses in CT26 tumor-bearing BALB/c mice[2].RBN-2397 (oral administration; 3-100 mg/kg; once daily; 32 days) causes complete regressions at the dose 100 mg/kg and exerts a dose-dependent effects on tumor growth at dose levels of ≥30 mg/kg[2].The half-life (t1/2) of RBN-2397 in vivo is 325 mins[2].
| ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 523.43 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C20H23F6N7O3 | ||||||||||||||||
CAS 号 | 2381037-82-5 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 200 mg/mL(382.10 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|